CTLA4 and congenital rubella syndrome: Most CTLA4 A17hom carriers received tisa-cel CAR-T cell therapy and showed favorable treatment outcomes, whereas half of the CTLA4 T17hom carriers received axi-cel CAR-T cell therapy, which was associated with increased CRS-related toxicity.